Alector Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative immune-neurology therapies designed to tackle neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, and related conditions. By leveraging human genetic insights and proprietary antibody engineering platforms, the company aims to restore normal immune system function in the central nervous system, clear pathological proteins, and slow or reverse the devastating progression of cognitive decline.